Received: 31 August 2020
Revised: 14 October 2020
Accepted: 25 November 2020
First Online: 12 December 2020
Compliance with ethical standards
: TM received research funding from MSD K.K., Novartis Pharma, LSI Medience, Medical & Biological Laboratories, Otsuka Pharmaceutical, Kyowa Kirin Co., Ltd., and Asahi Kasei Corporation, and personal fees from Pfizer Inc., MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma. TK received personal fees from Celgene, Bristol-Myers Squibb, Takeda Pharmaceutical, Otsuka Pharmaceutical, Eisai Pharmaceuticals, Sanofi K.K., and Janssen Pharma. MS received research funding from MSD K.K. and Nippon Shinyaku Co., Ltd., and personal fees from Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical, Eisai Co., Ltd., and Otsuka Pharmaceutical. MS received personal fees from Bristol-Myers Squibb, Novartis Pharma, Sumitomo Dainippon Pharma, Chugai Pharma, Meiji Seika Parma, and Nippon Shinyaku.